ZA986893B - Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same - Google Patents

Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same

Info

Publication number
ZA986893B
ZA986893B ZA986893A ZA986893A ZA986893B ZA 986893 B ZA986893 B ZA 986893B ZA 986893 A ZA986893 A ZA 986893A ZA 986893 A ZA986893 A ZA 986893A ZA 986893 B ZA986893 B ZA 986893B
Authority
ZA
South Africa
Prior art keywords
procedure
compound
pharmaceutical preparation
oral pharmaceutical
making same
Prior art date
Application number
ZA986893A
Other languages
English (en)
Inventor
Carlos Picornell Darder
Original Assignee
Intexim S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8300432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA986893(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intexim S A filed Critical Intexim S A
Publication of ZA986893B publication Critical patent/ZA986893B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
ZA986893A 1997-07-31 1998-07-31 Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same ZA986893B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009701816A ES2137862B1 (es) 1997-07-31 1997-07-31 Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.

Publications (1)

Publication Number Publication Date
ZA986893B true ZA986893B (en) 1999-01-27

Family

ID=8300432

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA986893A ZA986893B (en) 1997-07-31 1998-07-31 Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same

Country Status (33)

Country Link
US (1) US20020098242A1 (ja)
EP (1) EP1010423B1 (ja)
JP (1) JP3961217B2 (ja)
KR (1) KR100591488B1 (ja)
AR (1) AR013242A1 (ja)
AT (1) ATE317688T1 (ja)
AU (1) AU751609B2 (ja)
BG (1) BG64967B1 (ja)
CA (1) CA2307037C (ja)
CR (1) CR5826A (ja)
CZ (1) CZ298700B6 (ja)
DE (1) DE69833490T2 (ja)
DK (1) DK1010423T3 (ja)
ES (3) ES2137862B1 (ja)
GT (1) GT199800113A (ja)
HN (1) HN1998000113A (ja)
HR (1) HRP20000053B1 (ja)
HU (1) HU230635B1 (ja)
IL (1) IL134158A (ja)
MY (1) MY121353A (ja)
NO (1) NO20000435L (ja)
NZ (1) NZ502590A (ja)
PA (1) PA8456401A1 (ja)
PE (1) PE105199A1 (ja)
PL (1) PL192961B1 (ja)
PT (1) PT1010423E (ja)
RU (1) RU2207114C2 (ja)
SK (1) SK284892B6 (ja)
TR (1) TR200000264T2 (ja)
TW (1) TW533201B (ja)
UA (1) UA66800C2 (ja)
WO (1) WO1999006032A2 (ja)
ZA (1) ZA986893B (ja)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
TR200300731T2 (tr) 2000-11-28 2004-08-23 Fmc Corporation Yenebilir PGA kaplama bileşimi
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
KR100447085B1 (ko) * 2001-11-08 2004-09-04 바램제약주식회사 마그네슘이온, 칼슘이온 또는 철이온이 고농도로 결합된알긴산의 제조 방법
CA2466726C (en) * 2001-11-21 2011-02-22 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound and process for producing same
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
EP1524967B1 (en) * 2002-08-02 2008-03-12 Ratiopharm GmbH Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US20040162263A1 (en) * 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
EP1608347B1 (en) * 2003-03-28 2014-08-13 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
PT1729797E (pt) 2004-03-22 2008-12-17 Solvay Pharm Gmbh Composições farmacêuticas orais de produtos contendo lipase, em particular de pancreatina, contendo tensioactivos
RU2337687C2 (ru) * 2004-03-26 2008-11-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция с контролируемым высвобождением и способ ее получения
AU2005231145B8 (en) * 2004-03-31 2010-11-11 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
CA2581764A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Minicapsule formulations
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP2417969A1 (en) 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
BRPI0500586A (pt) * 2005-02-21 2006-10-10 Fundacao Oswaldo Cruz composição farmacêutica, processo para preparar dita composição, uso da respectiva composição no tratamento da imunodeficiência causada por infecção pelo hiv e respectivo método de tratamento
WO2006111980A2 (en) * 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1913138B1 (en) 2005-07-29 2016-08-24 Abbott Laboratories GmbH Processes for the manufacture of pancreatin powder with low virus content
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
JPWO2007037259A1 (ja) * 2005-09-29 2009-04-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 生体内での崩壊性を向上させたパルス製剤
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
SG186648A1 (en) 2007-02-20 2013-01-30 Aptalis Pharma Ltd Stable digestive enzyme compositions
WO2008122967A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited An oral pharmaceutical composition
WO2008132707A1 (en) 2007-04-26 2008-11-06 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2008132710A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
JPWO2009069280A1 (ja) * 2007-11-27 2011-04-07 大原薬品工業株式会社 造粒物の製造法
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
WO2009136398A2 (en) * 2008-05-06 2009-11-12 Dexcel Ltd Stable benzimidazole formulation
US8840934B2 (en) * 2009-01-02 2014-09-23 Rainbow Pharmaceutical Sa Uses of ammonium chloride
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
EP2464341B1 (en) 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
NZ600256A (en) 2009-12-02 2014-05-30 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them
US20110217426A1 (en) * 2010-03-04 2011-09-08 Perry Stephen C Enteric coating composition
UA111726C2 (uk) 2010-10-01 2016-06-10 Апталіс Фарма Лімітед Препарат панкреліпази низької сили з кишковорозчинним покриттям
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
JP6042880B2 (ja) * 2011-06-01 2016-12-14 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ 放出を制御された固形剤形
US10953025B2 (en) * 2011-07-14 2021-03-23 Able Cerebral, Llc Composition, device and method for delayed and sustained release of brain energy molecules
CN103945832B (zh) * 2011-07-14 2017-03-29 能脑有限责任公司 用于脑能量分子延迟释放和持续释放的组合物，装置及方法
EP2741766B1 (en) 2011-08-08 2015-10-07 Aptalis Pharma Limited Method for dissolution testing of solid compositions containing digestive enzymes
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2947998A1 (en) 2014-06-19 2015-12-23 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
MX2014008314A (es) * 2014-07-07 2016-01-06 Andres Abelino Choza Romero Procedimiento para mezclar sustancias, mediante nebulizacion.
TWI535784B (zh) 2014-08-26 2016-06-01 財團法人工業技術研究院 剪切增稠配方、及包含其之複合材料
EA036036B1 (ru) 2014-11-07 2020-09-16 Сигмойд Фарма Лимитед Композиции, содержащие циклоспорин
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
EP0642797B1 (en) * 1993-09-09 2000-05-17 Takeda Chemical Industries, Ltd. Formulation comprising antibacterial substance and antiulcer substance
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
HRP20000053A2 (en) 2000-08-31
CA2307037C (en) 2006-09-12
MY121353A (en) 2006-01-28
HU230635B1 (hu) 2017-05-29
PA8456401A1 (es) 2000-09-29
PL338613A1 (en) 2000-11-06
WO1999006032A2 (es) 1999-02-11
UA66800C2 (uk) 2004-06-15
HUP0002524A3 (en) 2002-12-28
CZ2000344A3 (cs) 2000-06-14
DE69833490T2 (de) 2006-10-19
CR5826A (es) 1998-09-28
NO20000435D0 (no) 2000-01-27
PL192961B1 (pl) 2006-12-29
ES2156699A1 (es) 2001-07-01
KR20010022439A (ko) 2001-03-15
NO20000435L (no) 2000-03-23
SK1032000A3 (en) 2000-11-07
EP1010423A2 (en) 2000-06-21
DK1010423T3 (da) 2006-05-22
US20020098242A1 (en) 2002-07-25
PT1010423E (pt) 2006-06-30
EP1010423B1 (en) 2006-02-15
AU751609B2 (en) 2002-08-22
HUP0002524A2 (hu) 2001-08-28
IL134158A0 (en) 2001-04-30
CA2307037A1 (en) 1999-02-11
BG104193A (en) 2000-09-29
ES2137862B1 (es) 2000-09-16
WO1999006032A3 (es) 1999-08-12
KR100591488B1 (ko) 2006-06-22
ES2256943T3 (es) 2006-07-16
RU2207114C2 (ru) 2003-06-27
JP3961217B2 (ja) 2007-08-22
ES2137862A1 (es) 1999-12-16
DE69833490D1 (de) 2006-04-20
TW533201B (en) 2003-05-21
HN1998000113A (es) 2000-01-06
PE105199A1 (es) 1999-11-19
BG64967B1 (bg) 2006-11-30
GT199800113A (es) 2000-01-18
ES2256943T4 (es) 2007-09-16
TR200000264T2 (tr) 2000-09-21
AU8217398A (en) 1999-02-22
SK284892B6 (sk) 2006-02-02
AR013242A1 (es) 2000-12-13
CZ298700B6 (cs) 2007-12-27
JP2001511443A (ja) 2001-08-14
NZ502590A (en) 2001-08-31
ES2156699B1 (es) 2002-03-01
HRP20000053B1 (en) 2003-10-31
ATE317688T1 (de) 2006-03-15
IL134158A (en) 2004-08-31

Similar Documents

Publication Publication Date Title
ZA986893B (en) Oral pharmaceutical preparation which includes a compound of anti-ulcer activity and procedure for making same
HUP0103708A3 (en) Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method
EG24044A (en) pharmaceutical formulation of omeprazole
IL131818A (en) Pharmaceutical composition for oral administration of a n-piperidino-3-pyrazolecarboxamide derivative, its salts and solvates and their preparation
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
HUP9903308A3 (en) Granuls for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
EG21973A (en) A new process for the preparation of a pharmacolgically active substance
IL187181A0 (en) Polymorph of a pharmaceutical
HU9502918D0 (en) Pharmaceutical composition of antihypertriglyceridemic activity
PL332249A1 (en) Pharmaceutical microspheres of varproinic acid for oral administration
HUP9800573A3 (en) Rapamycin formulations for oral administration and process for their preparation
PL307469A1 (en) Preparation for oral administration
HU9502426D0 (en) Compounds of pharmaceutical activity
ZA986320B (en) A method for the preparation of tertiary amines a compound useful therefor and alpha-2-receptor active tetrahyd-roisoquinoline derivatives
ZA987538B (en) A process for the preparation of solid oral dosage forms comprising alendronic acid
AU8885298A (en) Sustained-release oral preparation
SI1103252T1 (en) Pharmaceutical oral preparation of a compound having an antifungic activity, and preparation method
AU5384798A (en) Process for preparation of 4-deoxyerythromycins a and b
HU9700442D0 (en) Compounds of pharmaceutical activity
TJ217R3 (en) A method for the preparation of a substance having cholagogic and anti-inflammatory activity
HU9701917D0 (en) New compound of medicinal activity
AU6224299A (en) Pharmaceutical intermediate for the synthesis of fluoxetine and a process for the preparation thereof
TJ218R3 (en) A method for the preparation of a substance having cholagogic activity
TJ213R3 (en) A method for the preparation of a substance having immunostimulate activity
GB9408369D0 (en) Oral administration of protein drugs